Literature DB >> 10803833

Multimodality therapy of esophageal cancer: an update.

D P Kelsen1.   

Abstract

The incidence of adenocarcinoma of the esophagus is rapidly increasing in Western countries, particularly in Caucasian men. Both squamous cell carcinoma and adenocarcinoma are equally virulent tumors. In the absence of effective prevention and screening programs, most Western patients are found to have locally advanced or metastatic disease at the time of diagnosis. The outcome with regional therapy alone (either surgery or radiation) is poor. Multimodality therapy--treatment plans which include both systemic and regional treatments-is the focus of intense study. This review will summarize the current status of several different approaches that have the goal of increasing the cure rate in patients with newly diagnosed esophageal cancers.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10803833

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  7 in total

1.  [Regression of oesophageal carcinomas after neoadjuvant radiochemotherapy: criteria of the histopathological evaluation].

Authors:  S E Baldus; S P Mönig; W Schröder; R Metzger; S Lang; T K Zirbes; J Thiele; R P Müller; H P Dienes; A H Hölscher; P M Schneider
Journal:  Pathologe       Date:  2004-11       Impact factor: 1.011

2.  Plasma microRNAs to predict the response of radiotherapy in esophageal squamous cell carcinoma patients.

Authors:  Qi Yu; Bingxin Li; Ping Li; Zeliang Shi; Amanda Vaughn; Liucun Zhu; Shen Fu
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

3.  MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma.

Authors:  Niamh Lynam-Lennon; John V Reynolds; Laure Marignol; Orla M Sheils; Graham P Pidgeon; Stephen G Maher
Journal:  J Mol Med (Berl)       Date:  2012-06-17       Impact factor: 4.599

4.  Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification.

Authors:  Paul M Schneider; Stephan E Baldus; Ralf Metzger; Martin Kocher; Rudolf Bongartz; Elfriede Bollschweiler; Hartmut Schaefer; Juergen Thiele; Hans P Dienes; Rolf P Mueller; Arnulf H Hoelscher
Journal:  Ann Surg       Date:  2005-11       Impact factor: 12.969

5.  Emerging molecular targets in esophageal cancers.

Authors:  Julie G Izzo; Rajyalakshmi Luthra; Jennifer Sims-Mourtada; K S Clifford Chao; Jeffrey H Lee; Tsung-The Wu; Arlene M Correa; Madan Luthra; Bharat Aggarwal; Mien-Chie Hung; Jaffer A Ajani
Journal:  Gastrointest Cancer Res       Date:  2007

6.  Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer.

Authors:  F Miyazono; R Metzger; U Warnecke-Eberz; S E Baldus; J Brabender; E Bollschweiler; W Doerfler; R P Mueller; H P Dienes; T Aikou; A H Hoelscher; P M Schneider
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

7.  MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma.

Authors:  Becky A S Bibby; John V Reynolds; Stephen G Maher
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.